NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be given a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S announced that its Board of Directors has authorized a stock buyback program on Friday, February 2nd 2018, which allows the company to buyback shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, November, 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.62 by $0.02. The company earned $4.51 billion during the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

12 brokers have issued 12-month price objectives for Novo Nordisk A/S's shares. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

News headlines about NVO stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news impact score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.00%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and Brookmont Capital Management (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Brookmont Capital Management and Norman Fields Gottscho Capital Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was bought by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Janney Montgomery Scott LLC, We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, SeaCrest Wealth Management LLC, Atwater Malick LLC and Huntington National Bank. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $61.32.

Novo Nordisk A/S has a market capitalization of $145.21 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]